Proteoform-Resolved Profiling of Plasminogen Activation Reveals Novel Abundant Phosphorylation Site and Primary N-Terminal Cleavage Site.

Mol Cell Proteomics

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Science, University of Utrecht, Utrecht, The Netherlands; Netherlands Proteomics Centre, University of Utrecht, Utrecht, The Netherlands. Electronic address:

Published: January 2024

Plasminogen (Plg), the zymogen of plasmin (Plm), is a glycoprotein involved in fibrinolysis and a wide variety of other physiological processes. Plg dysregulation has been implicated in a range of diseases. Classically, human Plg is categorized into two types, supposedly having different functional features, based on the presence (type I) or absence (type II) of a single N-linked glycan. Using high-resolution native mass spectrometry, we uncovered that the proteoform profiles of human Plg (and Plm) are substantially more extensive than this simple binary classification. In samples derived from human plasma, we identified up to 14 distinct proteoforms of Plg, including a novel highly stoichiometric phosphorylation site at Ser339. To elucidate the potential functional effects of these post-translational modifications, we performed proteoform-resolved kinetic analyses of the Plg-to-Plm conversion using several canonical activators. This conversion is thought to involve at least two independent cleavage events: one to remove the N-terminal peptide and another to release the active catalytic site. Our analyses reveal that these processes are not independent but are instead tightly regulated and occur in a step-wise manner. Notably, N-terminal cleavage at the canonical site (Lys77) does not occur directly from intact Plg. Instead, an activation intermediate corresponding to cleavage at Arg68 is initially produced, which only then is further processed to the canonical Lys77 product. Based on our results, we propose a refined categorization for human Plg proteoforms. In addition, we reveal that the proteoform profile of human Plg is more extensive than that of rat Plg, which lacks, for instance, the here-described phosphorylation at Ser339.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10825491PMC
http://dx.doi.org/10.1016/j.mcpro.2023.100696DOI Listing

Publication Analysis

Top Keywords

human plg
16
plg
9
phosphorylation site
8
n-terminal cleavage
8
site
5
human
5
proteoform-resolved profiling
4
profiling plasminogen
4
plasminogen activation
4
activation reveals
4

Similar Publications

Fluphenazine (FPZ) is a well-known neuroleptic that has attracted considerable scientific interest due to its biocidal, virucidal, and antitumor properties. Although methods for encapsulating and delivering FPZ to enhance its activity and reduce side effects have been developed, there is still limited knowledge about its conjugates with gold nanoparticles (AuNPs). Therefore, the aim of this research was to develop a preparation method for stable FPZ-AuNP conjugates and to investigate their physicochemical and biological properties.

View Article and Find Full Text PDF

Establishing the reference intervals of plasma PLG, FXII activity, and FXIII antigen in healthy adults in Guangzhou.

BMC Cardiovasc Disord

January 2025

Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue Central, Guangzhou, 510280, P. R. China.

Objective: To establish the reference intervals of plasma Plasminogen, Factor XII activity, and Factor XIII Antigen in healthy adults in Guangzhou.

Methods: A total of 168 young people (75 males and 93 females, aged 18-65 years) who underwent physical examination in Zhujiang Hospital of Southern Medical University from 2020 to 2022 were recruited. Sysmex CS5100 automatic coagulation analyzer and matching reagents were used to detect Plasminogen.

View Article and Find Full Text PDF

We developed a novel adeno-associated virus 5 gene therapy (AAV5-GLA) expressing human alpha-galactosidase A (GLA) under the control of a novel, small and strong, liver-restricted promoter. We assessed the preclinical potential of AAV5-GLA for treating Fabry disease, an X-linked hereditary metabolic disorder resulting from mutations in the gene encoding GLA that lead to accumulation of the substrates globotriaosylceramide and globotriaosylsphingosine, causing heart, kidney, and central nervous system dysfunction. Effects of intravenously administered AAV5-GLA were evaluated in (1) GLA-knockout mice aged 7-8 weeks (early in disease) and 20 weeks (nociception phenotype manifestation) and (2) cynomolgus macaques during an 8-week period.

View Article and Find Full Text PDF

Evaluation of binding activities of a putative lipoprotein LIC_13355 of Leptospira spp.

FEBS Open Bio

December 2024

Laboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.

Pathogenic Leptospira is the etiological cause of the zoonotic life-threatening infection called leptospirosis. The disease is spread worldwide with higher risk in tropical regions. Although leptospirosis represents a burden to the health of humans and animals, the pathogenic mechanisms of Leptospira infection are yet to be clarified.

View Article and Find Full Text PDF

Attenuation of skin injury by a MARCO targeting PLGA nanoparticle.

NPJ Regen Med

December 2024

Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Article Synopsis
  • Exposure to nitrogen mustard, a type of chemotherapy, causes skin damage and inflammation due to the recruitment of immune cells that worsen the injury and hinder healing.
  • Administering poly(lactic-co-glycolic acid) immune-modifying nanoparticles (PLGA-IMPs) right after exposure can reduce harmful immune cell accumulation in the skin and improve healing outcomes.
  • PLGA-IMPs promote the presence of regulatory T cells that help control inflammation by producing key anti-inflammatory cytokines, suggesting a potential treatment strategy for severe skin injuries.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!